NasdaqHealth CareHealth Care TechnologyS&P SmallCap 600
$37.34
-0.69 (-1.81%)
Close of Nov 06, 2026 · end-of-day data
OMCL 8-K filings in 2024
Every material Form 8-K Omnicell filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Omnicell completed a private offering of $172.5 million of 1.00% convertible senior notes due December 1, 2029 on November 22, 2024, including the full exercise of a $22.5 million option. The company used about $391.2 million in cash, together with net proceeds of about $166.0 million, to repurchase $400.0 million of its 0.25% convertible notes due 2025. The filing shows a refinancing of near-term convertible debt with longer-dated debt, with potential dilution to shareholders if the notes convert into stock.
Offering totaled $172.5 million, including $22.5 million from the initial purchasers' option, and closed November 22, 2024.
Notes bear 1.00% annual interest and mature December 1, 2029; the initial conversion price is about $57.25 per share, a premium of about 35% to the November 19, 2024 closing price.
Net proceeds were about $166.0 million; about $391.2 million in cash was used to repurchase $400.0 million of 2025 notes.
The company may not redeem the notes before December 6, 2027.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Omnicell filing is on SEC EDGAR ↗. 8-K briefs of other companies →